ResMed stock holds near analyst target as latest quarter beats expectations
Published on 09/01/2026 at 10:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (US7611521078) stock is currently priced very close to the average 12-month analyst target after the company delivered stronger earnings and solid revenue growth in its most recent reported quarter, which ended in August 2026 as of August 28, 2026 per market data. The alignment between the share price and consensus valuation frames a steady picture for investors who are tracking the respiratory care specialist in the medical equipment space.
Per data compiled from analyst forecasts updated on September 1, 2026, the consensus 12-month price target for ResMed stands at $239.38, while the latest closing price on August 28, 2026 was $240.47, implying a forecast downside of 0.45 percent from that level. The fact that the share price trades slightly above the average target underscores how the market has already priced in the recent earnings strength, leaving limited upside in the current consensus view.
Latest quarter shows higher earnings and revenue
In its latest quarterly earnings release for the period ending in early August 2026, ResMed reported earnings per share of $2.95, ahead of the consensus estimate of $2.89 by $0.06, as reflected in recent coverage of the company’s results. That beat against expectations signals that the core operations are delivering incremental profitability beyond what analysts had modeled for the medical equipment provider.
The same quarterly report showed revenue of $1.46 billion, matching the $1.46 billion level that analysts had forecast for the period, according to the same earnings summary. While the top line came in line with expectations, the company still managed to expand revenue by 8.6 percent compared with the same quarter a year earlier, when sales were $1.34 billion, highlighting ongoing demand for ResMed’s sleep and respiratory care solutions.
That 8.6 percent revenue increase builds on prior growth, given that the company posted earnings per share of $2.55 in the corresponding quarter of the previous year. The roughly $0.40 year-over-year EPS improvement reflects both higher volumes and margin discipline, together supporting a return on equity of 25.58 percent and a net margin of 26.94 percent for the latest quarter, according to the same set of figures.
Analyst consensus and valuation context
Analyst sentiment toward ResMed currently clusters around a Hold stance, with a total of 17 research firms providing ratings over the last 12 months. Out of those, 10 have assigned a Hold rating and 7 have issued a Buy rating, resulting in an overall consensus rating of Hold for the shares based on this coverage snapshot updated on September 1, 2026.
The average 12-month price target of $239.38 derives from a range of scenarios, with the highest target at $300.00 and the lowest at $213.00 for the same period. With ResMed stock last closing at $240.47 on August 28, 2026, this target range suggests that some analysts still see meaningful upside while others are more cautious, but collectively they expect the stock to either consolidate or ease slightly from its recent level.
From a valuation standpoint, the fact that the stock trades marginally above the consensus target while the company is forecast to deliver earnings per share of 12.03 for the current fiscal year indicates that the market already rewards ResMed’s strong profitability profile. The combination of a mid-20s net margin and the forecasted full-year EPS leaves investors weighing whether future growth in sleep apnea and ventilation devices can push earnings sufficiently higher to justify more aggressive price targets.
Sleep apnea devices remain a core driver
ResMed’s business is anchored in medical devices and cloud-connected solutions that help manage sleep apnea and other chronic respiratory conditions, with its continuous positive airway pressure (CPAP) and bilevel devices forming a key part of the portfolio. These systems deliver pressurized air via masks and tubing to keep a patient’s airway open during sleep, reducing interruptions and improving quality of rest, which in turn supports cardiovascular and metabolic health.
The company’s platform strategy integrates these devices with software and data services that allow clinicians and providers to monitor adherence, adjust settings, and manage populations more efficiently. This blend of hardware, software, and data helps drive higher recurring revenue from masks, accessories, and digital services, which supports the stable margins evident in the latest quarter’s 26.94 percent net margin. For investors, the resilience of this treatment category is a central consideration when assessing ResMed’s long-term earnings power.
ResMed stock level and recent trading
As of August 28, 2026, at 3:58 p.m. ET, ResMed stock closed at $240.47 on the New York Stock Exchange, with a small gain of $0.14, or 0.06 percent, on the day according to the latest closing snapshot. That price sits essentially in line with the consensus 12-month target of $239.38, reinforcing the picture of a stock that already reflects the current outlook embedded in analyst models.
The narrow gap between the current share price and the average target means that short-term moves may be more sensitive to new information, such as upcoming earnings or changes in demand for respiratory therapy. With the company operating as a medical equipment provider in a structurally growing market, the recent earnings beat and revenue growth create a foundation for the stock’s present valuation, but the consensus Hold rating suggests that analysts are waiting for further catalysts before revising their targets materially higher.
Go deeper
Read more on the latest ResMed stock forecasts in a detailed analyst overview.
Fact box
Company: ResMed Inc.
ISIN: US7611521078
Ticker: RMD
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 3:58 p.m. ET): $240.47 USD
Sector / Industry: Health care - Medical equipment
Index membership: S&P 500
